J&J Takes a $5.5 Billion Talc Charge as MedTech Growth Slows From 7.7% to 2.5%
Johnson & Johnson (JNJ) reported Q3 sales of $25.40B (+5.9% YoY) and adjusted EPS of $2.59, beating estimates. A $5.5B talc-related charge reduced GAAP EPS to $0.09. MedTech revenue growth slowed to 2.5%, while Pharma sales rose 7.7%. JNJ raised 2026 guidance slightly but shares fell 4% on MedTech concerns.
How this was made
The 30-second read
Why it matters
The key trade is whether investors price the talc settlement as a contained, near-term earnings drag versus a continuing overhang, alongside whether MedTech growth stabilizes after two quarters of deceleration.
Market read
Despite an adjusted EPS beat and a small outlook raise, the combination of a large litigation charge and fading MedTech growth is a direct catalyst for valuation and sentiment.
What to watch
The settlement’s opt-in requirement (95% of claimants) and the cap on additional payments (no more than $3B in 2027) may reduce tail risk versus a larger, open-ended liability, but the article does not quantify probability of opt-in failure.
Background
J&J reported Q3 results with a major GAAP hit from a pretax ovarian talc litigation charge, while adjusted earnings beat and guidance was slightly raised.
Ticker impact
Johnson & Johnson disclosed a $5.52B pretax ovarian talc litigation charge tied to a $5.5B settlement offer, alongside slowing MedTech growth and a small outlook raise.
Likely near-term pressure as the market weighs the one-time charge versus whether MedTech growth continues to fade.
The article attributes the quarter’s profit hit to the $5.52B charge and shows MedTech growth falling from 7.7% to 2.5% over successive quarters, while the guidance raise is described as too small to offset the slowdown.
Market effects
Reinforces that large pharma-medtech hybrids can see earnings quality and valuation sensitivity to litigation charges and device growth deceleration.
Limited direct regional spillover; primarily affects US large-cap healthcare sentiment around litigation-cost normalization.
Moderate read-through for global healthcare investors on how settlement opt-in mechanics and MedTech pricing pressures can weigh on earnings durability.
Counterpoint
The talc charge is explicitly labeled one-time, and the company still beat estimates and raised 2026 outlook, which could support a rebound if investors treat the settlement as a path to closure.
Key entities
- companyJohnson & Johnson
Reported a $5.52B pretax ovarian talc litigation charge tied to a $5.5B settlement offer and showed MedTech growth slowing to 2.5% in the quarter.
